Efficacy News and Research

RSS

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.

3 Mar 2014

New methodology for rapid detection of antibiotics in blood paves way to drug development, personalized treatment

A new methodology for rapidly measuring the level of antibiotic drug molecules in human blood serum has been developed, paving the way to applications within drug development and personalised medicine.

3 Mar 2014

Gastric bypass better than gastrectomy for GERD relief

Patients who are about to undergo bariatric surgery may be better off having a gastric bypass than a sleeve gastrectomy if they also suffer from heartburn, results of a large US analysis suggest.

28 Feb 2014

Xeltis completes enrollment for study of spontaneous tissue growth technology

Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. With its proprietary technology, the company has pioneered an entirely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use unique implants designed to allow the body to repair itself by growing natural, healthy tissue.

28 Feb 2014

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.

28 Feb 2014

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adding motesanib to carboplatin/paclitaxel significantly improves overall survival in Asian patients with nonsquamous non-small-cell lung cancer compared with carboplatin/paclitaxel alone, researchers report.

27 Feb 2014

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

27 Feb 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.

27 Feb 2014

Phase 2 trial results show GPB reduces hepatic encephalopathy episodes in patients with cirrhosis

Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to reduce hepatic encephalopathy episodes in patients with cirrhosis, with a safety profile similar to placebo.

27 Feb 2014

Attitudinal beliefs feed negative schizophrenia symptoms

Dysfunctional attitudes and low self-efficacy are associated with poorer functioning in patients with early schizophrenia, and this relationship is partly mediated by negative symptoms, shows research.

26 Feb 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Santalis Pharmaceuticals Inc., a joint venture with TFS Corporation Ltd., of Australia (ASX: TFC) is pleased to report the execution of an exclusive license agreement with a global pharmaceutical company for the marketing of a number of over-the-counter (OTC) dermatology products containing TFS' sustainably cultivated, pharmaceutical-grade East Indian Sandalwood Oil (EISO).

26 Feb 2014

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

K-PAX Pharmaceuticals is working with Stanford University and several other leading research institutions to perform a Phase II double-blind, placebo-controlled trial to evaluate the safety and efficacy of a currently available FDA-approved medication concurrently administered with a novel mitochondrial support product in order to identify a safe and effective treatment for the chronic fatigue and decreased alertness (i.e. brain fog) that commonly afflicts people with CFS.

26 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests.

25 Feb 2014

Detrusor muscle function declines with age

Detrusor muscle function and efficiency decline with increasing age, a urodynamic study of women with stress urinary incontinence indicates.

25 Feb 2014

Healthy Directions launches Krill Omega Defense

Healthy Directions, LLC, today announced the launch of Krill Omega Defense™, a unique krill supplement formulated by Julian Whitaker, MD, that supports and maintains the health of the body's key biological functions and systems—from the heart, brain, and nerves to the eyes and bones.

25 Feb 2014

Dieters more likely to give in to alcoholic temptations than to sugary snacks

There's more to dieting than just sheer willpower and self-control. The presence of friends, late night cravings or the temptation of alcohol can often simply be too strong to resist.

25 Feb 2014

Efficacy News and Research

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

New methodology for rapid detection of antibiotics in blood paves way to drug development, personalized treatment

Gastric bypass better than gastrectomy for GERD relief

Xeltis completes enrollment for study of spontaneous tissue growth technology

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Phase 2 trial results show GPB reduces hepatic encephalopathy episodes in patients with cirrhosis

Attitudinal beliefs feed negative schizophrenia symptoms

FDA approves KALYDECO for people with cystic fibrosis

Santalis Pharmaceuticals partners with TFS for marketing of OTC dermatology products

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

K-PAX Pharmaceuticals works with Stanford University to identify effective treatment for chronic fatigue

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Detrusor muscle function declines with age

Healthy Directions launches Krill Omega Defense

Dieters more likely to give in to alcoholic temptations than to sugary snacks

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News